DE69828442T2 - Kombinationspräparate enthaltend statin und karboxyalkyläther - Google Patents

Kombinationspräparate enthaltend statin und karboxyalkyläther Download PDF

Info

Publication number
DE69828442T2
DE69828442T2 DE69828442T DE69828442T DE69828442T2 DE 69828442 T2 DE69828442 T2 DE 69828442T2 DE 69828442 T DE69828442 T DE 69828442T DE 69828442 T DE69828442 T DE 69828442T DE 69828442 T2 DE69828442 T2 DE 69828442T2
Authority
DE
Germany
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
statin
kit
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828442T
Other languages
German (de)
English (en)
Other versions
DE69828442D1 (de
Inventor
Larry Charles BISGAIER
Schofield Roger NEWTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69828442D1 publication Critical patent/DE69828442D1/de
Application granted granted Critical
Publication of DE69828442T2 publication Critical patent/DE69828442T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE69828442T 1997-12-12 1998-11-20 Kombinationspräparate enthaltend statin und karboxyalkyläther Expired - Lifetime DE69828442T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12
US69375P 1997-12-12
PCT/US1998/024679 WO1999030704A1 (en) 1997-12-12 1998-11-20 Statin-carboxyalkylether combinations

Publications (2)

Publication Number Publication Date
DE69828442D1 DE69828442D1 (de) 2005-02-03
DE69828442T2 true DE69828442T2 (de) 2005-06-02

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828442T Expired - Lifetime DE69828442T2 (de) 1997-12-12 1998-11-20 Kombinationspräparate enthaltend statin und karboxyalkyläther

Country Status (30)

Country Link
EP (1) EP1045691B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002508320A (cg-RX-API-DMAC7.html)
KR (1) KR20010033003A (cg-RX-API-DMAC7.html)
AR (1) AR017851A1 (cg-RX-API-DMAC7.html)
AT (1) ATE285762T1 (cg-RX-API-DMAC7.html)
AU (1) AU754089B2 (cg-RX-API-DMAC7.html)
BR (1) BR9813542A (cg-RX-API-DMAC7.html)
CA (1) CA2304612A1 (cg-RX-API-DMAC7.html)
CO (1) CO4970816A1 (cg-RX-API-DMAC7.html)
CR (1) CR5926A (cg-RX-API-DMAC7.html)
CU (1) CU20000140A7 (cg-RX-API-DMAC7.html)
DE (1) DE69828442T2 (cg-RX-API-DMAC7.html)
DK (1) DK1045691T3 (cg-RX-API-DMAC7.html)
ES (1) ES2230733T3 (cg-RX-API-DMAC7.html)
GT (1) GT199800196A (cg-RX-API-DMAC7.html)
HN (1) HN1998000185A (cg-RX-API-DMAC7.html)
HU (1) HUP0004547A3 (cg-RX-API-DMAC7.html)
IL (1) IL135349A0 (cg-RX-API-DMAC7.html)
IS (1) IS2150B (cg-RX-API-DMAC7.html)
MY (1) MY118381A (cg-RX-API-DMAC7.html)
NO (1) NO20002966L (cg-RX-API-DMAC7.html)
NZ (1) NZ503982A (cg-RX-API-DMAC7.html)
PA (1) PA8464601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20000017A1 (cg-RX-API-DMAC7.html)
PL (1) PL341066A1 (cg-RX-API-DMAC7.html)
PT (1) PT1045691E (cg-RX-API-DMAC7.html)
SV (1) SV1998000146A (cg-RX-API-DMAC7.html)
UY (1) UY25299A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999030704A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9811348B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
CA2299397A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
CZ20011035A3 (cs) * 1998-09-30 2001-10-17 Warner-Lambert Company Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (cg-RX-API-DMAC7.html) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
NZ519550A (en) 2000-01-25 2003-11-28 Warner Lambert Co Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
CZ20023459A3 (cs) * 2000-04-26 2003-05-14 Warner-Lambert Company Antihypertensní činidla a jejich použití
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
JP6295205B2 (ja) * 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. 心血管疾患のリスクを低減する方法
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
NO20002966D0 (no) 2000-06-09
IL135349A0 (en) 2001-05-20
JP2002508320A (ja) 2002-03-19
EP1045691B1 (en) 2004-12-29
IS5445A (is) 2000-04-14
ES2230733T3 (es) 2005-05-01
GT199800196A (es) 2000-06-03
SV1998000146A (es) 1999-09-30
WO1999030704A1 (en) 1999-06-24
EP1045691A1 (en) 2000-10-25
HN1998000185A (es) 1999-06-02
CR5926A (es) 2000-03-06
DE69828442D1 (de) 2005-02-03
CA2304612A1 (en) 1999-06-24
KR20010033003A (ko) 2001-04-25
NO20002966L (no) 2000-06-09
BR9813542A (pt) 2000-10-10
AU1591599A (en) 1999-07-05
HUP0004547A3 (en) 2001-12-28
IS2150B (is) 2006-10-13
PA8464601A1 (es) 2001-12-14
MY118381A (en) 2004-10-30
CO4970816A1 (es) 2000-11-07
NZ503982A (en) 2002-03-28
PL341066A1 (en) 2001-03-26
AR017851A1 (es) 2001-10-24
ATE285762T1 (de) 2005-01-15
DK1045691T3 (da) 2005-03-14
ZA9811348B (en) 1999-06-14
PT1045691E (pt) 2005-03-31
CU20000140A7 (es) 2005-10-19
HUP0004547A2 (hu) 2001-05-28
AU754089B2 (en) 2002-11-07
PE20000017A1 (es) 2000-01-20
UY25299A1 (es) 2001-08-27

Similar Documents

Publication Publication Date Title
DE69826683T2 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
DE69828413T2 (de) Kombinationstherapie, enthaltend atorvastatin und bluddrucksenkendes mittel
DE60035581T2 (de) Salz von amlodipin und atorvastatin
US20020025981A1 (en) Combination therapy
CZ2003390A3 (en) Therapeutic combination of a cetp inhibitor and atorvastatin
DE3115383A1 (de) Antiallergisches mittel
EP1045691B1 (en) Statin-carboxyalkylether combinations
DE60011424T2 (de) Gegenseitige prodrugs von amlopidin und atorvastatin
DE3390114T1 (de) Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung
DE69915084T2 (de) Methode zur vermeidung oder verzögerung von katheterbedingter gefässrückbildung
WO1995028919A1 (de) ARZNEIMITTEL ENTHALTEND p-OXYBENZOESÄUREDERIVAT UND FIBRAT
US8557835B2 (en) Statin-carboxyalkylether combinations
DE60107559T2 (de) Kombination von carboxyalkylethern mit antihypertensiva und pharmazeutische verwendung
DE60124400T2 (de) Verwendung eines betablockers zur behandlung von atherosklerose
US20020103252A1 (en) Statin-carboxyalkylether combinations
AU1306099A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
DE1767094C3 (de) Veränderung des Fettstoffwechsels sowie Reduzierung des Blutcholesterinspiegels
US20030225123A1 (en) Antihypertensive agents and use
EP1481962A1 (en) New cholesterolemia-lowering carboxyalkylether compound
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
WO1995028924A1 (de) KOMBINATIONSPRÄPARATE MIT EINEM GEHALT AN EINEM p-OXYBENZOESÄUREDERIVAT, Z.B. LIFIBROL, UND EINEM HMG-CoA-REDUKTASE-HEMMER, Z.B. LOVASTATIN, PRAVASTATIN ODER SIMVASTATIN
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
8364 No opposition during term of opposition